AMVUTTRA dominates, but Medicare and policy hurdles slow growth
- Alnylam is the definitive leader in RNA interference, a drug method that turns down harmful genes.
- The AMVUTTRA launch is scaling fast, reaching $1.15 billion in TTR revenues during the third quarter of 2026.
- Management expects to hit the low end of its $4.2 billion to $4.5 billion TTR revenue guidance as prescriber engagement translates slowly.
- New headwinds include a restrictive UnitedHealth access policy and a proposed CMS 340B reimbursement cut.
- The hard parts include regulatory marketing scrutiny, a margin ceiling near 30 percent, and relying heavily on a single franchise.
A massive launch meets reality
Alnylam has moved from a promising biotech to a real commercial drug company. The key reason is AMVUTTRA. The drug crossed $1 billion in quarterly revenue in mid-2026 and hit $1.15 billion in TTR revenues in the third quarter. The competitive landscape also shifted in Alnylam's favor when rival drug eplontersen failed its Phase 3 study, cementing the company as the leader in ATTR cardiomyopathy.
The bull case is built on this commercial strength. Alnylam leads RNAi, has several approved drugs, and secured a new distribution partnership with BeOne for AMVUTTRA in China and Macau. Its Alnylam 2030 plan targets 25 percent or more total revenue compound annual growth and about a 30 percent non-GAAP operating margin by 2030. Promising Phase 1 data for brezosiran in Huntington's disease adds another potential long-term growth driver.
The bear case centers on the pace of that growth and new policy headwinds. Management expects to land at the low end of its 2026 TTR guidance range. Expanding the sales force has brought in new prescribers, but those doctors are not starting patients on therapy as fast as expected. The initial wave of pent-up demand from second-line patients exhausted faster than anticipated.
The stock also carries regulatory and access questions. A restrictive AMVUTTRA policy implemented by UnitedHealth and a pending CMS 340B rule change both threaten to squeeze volume and price. Heavy Phase 3 research spending and royalty burdens mean profits may not scale as fast as top-line revenue, while FDA scrutiny over marketing adds risk to the story.
Drug sales first, partner checks second
Alnylam makes money in three ways: selling its own drugs, collecting collaboration revenue from partners, and earning royalties on partner-sold drugs. Its four self-marketed products are AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO.
The direct drug business is now much larger than the rest. The TTR franchise is the primary driver, with AMVUTTRA representing a multi-billion dollar annual run rate. This shows how concentrated the business has become around one main therapy.
Partner revenue adds useful funding and geographic reach. Novartis sells Leqvio, Sanofi sells Qfitlia, Roche is partnered on zilebesiran, and BeOne is now the exclusive commercial distributor for AMVUTTRA in Mainland China and Macau. Royalties from Novartis and Sanofi provide high-margin cash flow.
The model breaks if AMVUTTRA loses share or if pricing gets worse. With new access policies from major insurers and proposed Medicare rule changes, the company must prove it can sustainably find and treat new first-line patients while protecting its profit margins.
Approved drugs and big bets
AMVUTTRA
AMVUTTRA treats hATTR amyloidosis with polyneuropathy and ATTR cardiomyopathy. It is the primary growth driver for the entire company.
ONPATTRO
ONPATTRO treats the polyneuropathy form of hATTR amyloidosis. It is older than AMVUTTRA, and many patients have switched to the newer drug.
GIVLAARI and OXLUMO
GIVLAARI treats acute hepatic porphyria, and OXLUMO treats primary hyperoxaluria type 1. They give Alnylam rare disease revenue outside TTR.
Leqvio and Qfitlia royalties
Leqvio is sold by Novartis, and Qfitlia is sold by Sanofi. These drugs add high-margin royalty revenue without Alnylam running the sales effort.
Nucresiran
Nucresiran is a next-generation TTR program. A Phase 3 cardiomyopathy study, TRITON-CM, expanded enrollment to 2,250 patients due to lower background event rates.
Zilebesiran
Zilebesiran is an RNAi treatment for hypertension, partnered with Roche. A Phase 3 cardiovascular outcomes trial is expected to start in the second half of 2025.
Brezosiran and obesity program
Brezosiran showed strong reductions in mutant huntingtin in Phase 1, paving the way for Phase 3. Alnylam also has a Phase 1 adipose-targeted obesity program underway.
Product sales dominate the mix
This mix reflects the middle of the 2026 fiscal year, broken into net product revenue, collaboration revenue, and royalty revenue. Product sales dominate entirely.
What could break the story
Payer access and 340B cuts
High impact · High oddsA proposed CMS rule change could reduce Medicare reimbursement in the 340B channel, while UnitedHealth implemented a restrictive first-line policy for AMVUTTRA. If these policies stick, they will pressure patient starts and gross-to-net pricing.
AMVUTTRA new patient starts stall
High impact · Medium oddsAlnylam expects to land at the low end of its 2026 TTR guidance. Expanding the sales force has brought in new prescribers, but these doctors are struggling with buy-and-bill hurdles and not starting patients as fast as hoped.
FDA promotion scrutiny restricts marketing
Medium impact · Medium oddsIn April 2026, the FDA sent Alnylam an untitled letter saying parts of the AMVUTTRA consumer website were false and misleading. That followed a similar September 2025 letter. More action could force changes in marketing and slow patient outreach.
Government price reporting investigation
High impact · Low oddsAlnylam received a subpoena from the U.S. Attorney's Office related to government price reporting for its four commercial products. If violations are found, significant financial penalties and management distraction could follow.
Pipeline clinical trials fail
Medium impact · Medium oddsAlnylam needs follow-on programs to make the 2030 plan work. TRITON-CM enrollment had to be expanded to offset lower event rates. Failed trials for nucresiran or brezosiran would lower the long-term growth case significantly.
In one breath
What does Alnylam actually do?
Alnylam develops RNAi medicines. RNAi drugs are designed to silence, or turn down, genes that help cause disease.
Why is AMVUTTRA so important to Alnylam?
AMVUTTRA is the main growth engine after its ATTR cardiomyopathy launch. It now generates over a billion dollars in quarterly revenue.
Is Alnylam profitable?
Alnylam reported its first full-year GAAP profitability in 2025. Management targets a 30 percent non-GAAP operating margin by 2030, but royalties and research spending limit how fast profits scale.
What is the biggest risk for ALNY stock?
The biggest risk is that Medicare reimbursement cuts and restrictive insurance policies slow AMVUTTRA growth. Other key risks are FDA scrutiny of promotion and a government price reporting subpoena.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- November 1, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Biotechnology companies
Companies near Alnylam Pharmaceuticals, Inc. in Finn's Biotechnology industry ranking.

